Abstract:Importance: Meningiomas are the most common primary brain tumor and a heterogeneous disease with a need to study response to surgery and adjuvant RT in the context of contemporary molecular classifications. Objective: The gold standard for treatment of symptomatic meningiomas has been surgical resection including complete removal of tumor and its surrounding dural margin, although the necessity of different degrees of marginal resection is controversial. Adjuvant radiotherapy (RT) is generally reserved for aggressive or subtotally resected (STR) meningiomas. However, uncertainty exists regarding optimal case selection for RT and response to treatment is variable. We aimed to examine the effects of treatment (surgery/RT), molecular, and clinical factors on meningiomas in the context of molecular classifications. Design, Setting, and Participants: In this retrospective analysis, a 20-year cohort of 2490 patients with meningiomas were assembled across 10 institutions. Molecular data (DNA methylation, RNA sequencing) was generated for 1645 cases. Propensity score matching (PSM) was performed for key baseline covariates including WHO grade and molecular classifications, mimicking a randomized, molecular pathology informed clinical trial. Main Outcome and Measures: Progression-free survival (PFS), and overall survival (OS) were assessed based on extent of resection (EOR), Simpson grade, and receipt of adjuvant RT. Results: Gross total resection (GTR) was associated with improved PFS across all molecular groups. The PFS benefit of GTR was lessened in molecularly-defined proliferative meningiomas (HR 0.69, 95%CI 0.50-0.95), but OS benefit was enhanced (HR 0.52, 95%CI 0.30-0.93). Surgically treating the dural margin (Simpson grade 1/2) was associated with improved PFS compared to removal of tumor alone (Simpson grade 3) particularly for immunogenic (HR 0.16, 95%CI 0.03-0.82) and NF2-wildtype meningiomas (HR 0.24, 95%CI 0.11-0.53). Adjuvant RT was associated with improved PFS across all molecular classifications. Molecular groups could reliably predict response to RT, even when controlling for WHO grade and EOR with immunogenic and NF2-wildtype meningiomas benefitting most while proliferative meningiomas are largely RT-resistant (HR 0.96, 95%CI 0.67-1.37). Conclusion: This study is the first to investigate interactions between contemporary molecular classifications and response to both surgical resection and adjuvant RT in a large, multi-institutional cohort of molecularly defined, clinically annotated meningioma cases. Citation Format: Justin Z. Wang, Alexander P. Landry, Vikas Patil, Andrew Ajisebutu, Christopher D. Wilson, Aaron Cohen-Gadol, Ghazaleh Tabatabai, Silky Chotai, Jill Barnholtz-Sloan, Rebecca Yakubov, Mark Wilson, Ramneet Kaloti, Alexander Rebchuk, Damian A. Almiron Bonnin, Eric C. Holland, Stephen Yip, Felix Sahm, Kenneth Aldape, The International Consortium on Meningiomas, Farshad Nassiri, Gelareh Zadeh. Meningioma molecular classification predict response to surgical resection and adjuvant radiotherapy: An integrated clinicomolecular analysis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 2346.

Genomic Landscape of Meningiomas.

Meningioma transcriptomic landscape demonstrates novel subtypes with regional associated biology and patient outcome

Correlations Between Genomic Subgroup and Clinical Features in a Cohort of More Than 3000 Meningiomas.

High Copy-Number Variation Burdens in Cranial Meningiomas From Patients With Diverse Clinical Phenotypes Characterized by Hot Genomic Structure Changes

Epco-39. Multiomic And Clinical Analysis Of Multiply Recurrent Meningiomas Reveals Risk Factors, Underlying Biology, And Insights Into Evolution

Whole-Genome Sequencing Identifies New Genetic Alterations in Meningiomas

Meningioma: current updates on genetics, classification, and mouse modeling

Spatial genomic, biochemical and cellular mechanisms underlying meningioma heterogeneity and evolution

Somatic Mutation Landscape of a Meningioma and Its Pulmonary Metastasis

Genomic Profiling Reveals Alternative Genetic Pathways of Meningioma Malignant Progression Dependent on the Underlying NF2 Status.

Whole exome sequencing of multiple meningiomas with varying histopathological presentation in one patient revealed distinctive somatic mutation burden and independent clonal origins.

Biom-60. Understanding The Intersection Of Race, Sex, And Genomic Profiles In Meningioma Pathophysiology

Molecular classification to refine surgical and radiotherapeutic decision-making in meningioma

Genomic Analysis of Primary and Recurrent Gliomas Reveals Clinical Outcome Related Molecular Features.

A targeted gene expression biomarker predicts clinic low-risk meningioma recurrence

Surg-03. Gene Expression Changes Associated With Recurrence After Gross Total Resection Of Newly Diagnosed Who Grade 1 Meningioma

206 Spinal Meningioma: An Institutional Case Series With Preliminary Results of Molecular Profiling

Molecular landscapes of longitudinal NF2/22q and non‐NF2/22q meningiomas show different life histories

Is DNA Methylation a Ray of Sunshine in Predicting Meningioma Prognosis?

Biom-16. A Targeted Gene Expression Biomarker Predicts Low Grade Meningioma Recurrence And Overall Survival

Abstract 2346: Meningioma molecular classification predict response to surgical resection and adjuvant radiotherapy: An integrated clinicomolecular analysis